Original language | English |
---|---|
Journal | The Lancet |
Publication status | Accepted/In press - 19 May 2016 |
LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)
Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana Vasconcelos, Caroline Murphy, Joanna Kelly, J.E Brazier, Hasan Basarir, Simon Harding, Yit Yang, Usha Chakravarthy, Andrew J Lotery
Research output: Contribution to journal › Article › peer-review
19
Downloads
(Pure)